14684
We report three patients , all of whom had preexisting diabetic dyslipidemia , who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy .
 adverse effect: reduction in plasma HDL cholesterol and apolipoprotein AI levels, rosiglitazone
Given options, please tell me the relationships of all the listed entity pairs.Output format is "relation1: word1, word2; relation2: word3, word4". 
Option: adverse effect 
Text: {0} 
 Entity Pairs:  reduction in plasma HDL cholesterol and apolipoprotein AI levels, rosiglitazone 
Answer:
 adverse effect: reduction in plasma HDL cholesterol and apolipoprotein AI levels, rosiglitazone